Atreca, BeiGene and IGM Biosciences have partnered to identify, develop, and manufacture new immunoglobulin M (IgM) and immunoglobulin A (IgA) antibody therapeutics for Covid-19 infection.
In the wake of the ongoing pandemic, the partners will start work immediately and finalise financial details, as well as other terms, later in the future.
The human immune system naturally generates IgM and IgA antibodies. IGM Biosciences engineers these antibodies with higher binding power per antibody to potentially enable better activity against different variants of SARS-CoV-2, the novel coronavirus that causes Covid-19.